Genentech: Katie Hutchinson | Senior Principal Scientist Development, Oncology Biomarker Development, Translational Medicine

Scientists / Our Scientists

"Every day is an adventure. I am amazed and humbled to be working alongside such talented individuals utilizing advanced scientific insights to drive toward a singular goal - to bring potentially life-changing, personalized therapies to patients with cancer."

Years at Genentech

Publications at Genentech

My career in biomarker science kicked off as a graduate student in the laboratory of William Pao at Vanderbilt University. Although the majority of William’s lab focused on molecular drivers of non-small cell lung cancer (NSCLC), through collaborative efforts with top medical oncologists at Vanderbilt, I had the opportunity to explore novel fusion events that drive a significant fraction of melanomas and pancreatic cancers. I subsequently joined the Vanderbilt laboratory of Carlos Arteaga for my post-doctoral studies where my focus shifted to determine potential mechanisms of resistance endocrine therapy and cell cycle regulator inhibition in patients with hormone receptor positive breast cancer.

This work led to an opportunity to join the Oncology Biomarker Development (OBD) group at Genentech in late 2016. Continuing my passion to match the right patients to the right therapeutic agents based on tumor- and blood-based biomarkers, I have assumed a number of exciting biomarker lead roles for precision oncology small molecule programs addressing needs for both adult and pediatric patients with cancer.

Featured Publication

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple Negative Breast Cancer Reveals Immune Phenotype Shifts.

Clin Cancer Res PMID: 31611282.

Hutchinson, K.E., Yost, S.E., Chang, C.W., Johnson, R.M., Schmolze, D., Liang, J., Yuan, Y. (2019)

View Abstract

My group focuses on (1) understanding mechanisms of response and resistance to PI3K-directed therapy in patients with hormone-receptor positive breast cancer treated with standard-of-care endocrine agents; (2) understanding opportunities for PI3K-directed intervention in combination with standard-of-care agents for non-breast oncology indications.

I also lead a cross-oncology group (i.e. signaling, heme, immunotherapy) of OBD scientists that support the Roche/Genentech pediatric oncology program to drive rational, biomarker-driven development of our therapies in pediatric patients with cancer.

Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study

European Journal of Cancer, ISSN: 09598049

Philippe L. Bedard; Komal Jhaveri; Melissa Accordino; Prof Andrés Cervantes; Valentina Gambardella; Hamilton; Prof Antoine Italiano; Prof Kevin Kalinsky; Prof Ian E. Krop; Oliveira; Prof Peter Schmid; Saura; Prof Nicholas Turner; Andrea Varga; Sravanthi Cheeti; Anwesha Dey; Stephanie Hilz; Katherine E. Hutchinson; Yanling Jin; Stephanie Royer-Joo; Ubong Peters; Noopur Shankar; Jennifer L. Schutzman; Junko Aimi; Kyung Song; Dejan Juric

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Katie Hutchinson

Senior Principal Scientist Development, Oncology Biomarker Development, Translational Medicine

Featured Publication

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple Negative Breast Cancer Reveals Immune Phenotype Shifts.